PRFX
PRF Technologies Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · IL
$0.97
−1.14%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 25.5K | 17.0K | — | — | 86.0K |
| Cost of Revenue | 105.0K | 844.0K | 16.0K | 15.0K | 15.0K |
| Gross Profit | (79.5K) | (827.0K) | (16.0K) | (15.0K) | 71.0K |
| Operating Expenses | |||||
| R&D Expense | 1.8M | 1.1M | 11.7M | 6.0M | 4.4M |
| SG&A Expense | 5.7M | 3.0M | 3.0M | 3.5M | 4.4M |
| General & Admin Expense | 5.5M | 3.0M | 3.0M | 3.5M | 4.4M |
| Selling & Marketing Expense | 244.5K | — | — | 66.0K | — |
| Other Expenses | 1.2M | — | — | — | — |
| Total Operating Expenses | 8.8M | 4.2M | 14.7M | 9.6M | 8.9M |
| Cost and Expenses | 8.9M | 5.0M | (14.7M) | 9.6M | 8.9M |
| Operating Income (EBIT) | (8.9M) | (5.0M) | (14.7M) | (9.6M) | (8.9M) |
| Non-Operating | |||||
| Interest Income | 143.5K | 120.0K | 101.0K | 406.0K | 160.0K |
| Interest Expense | — | 10.0K | 14.0K | 384.0K | 61.0K |
| Net Interest Income | 143.5K | 110.0K | 87.0K | 22.0K | 99.0K |
| Other Non-Op Income/Expense | 188.0K | (27.0K) | 93.0K | 248.0K | 86.0K |
| Non-Operating Income (excl Interest) | (108.0K) | — | (107.0K) | — | (99.0K) |
| EBT (Pre-Tax Income) | (8.7M) | (5.0M) | (14.6M) | (9.3M) | (8.8M) |
| Income Tax Expense | 12.0K | 8.0K | 8.0K | 8.0K | 9.0K |
| Bottom Line | |||||
| Net Income | (8.4M) | (4.8M) | (14.6M) | (9.3M) | (8.8M) |
| Earnings from Cont. Ops | (8.7M) | (5.0M) | (14.6M) | (9.3M) | (8.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (8.4M) | (4.8M) | (14.6M) | (9.3M) | (8.8M) |
| Per Share | |||||
| Basic EPS | ($36.42) | ($7.47) | ($804.00) | ($4,283.23) | ($4,948.02) |
| Diluted EPS | ($36.42) | ($7.47) | ($804.00) | ($4,283.23) | ($4,948.02) |
| Revenue Per Share | $0.04 | $0.03 | $0.00 | $0.00 | $48.40 |
| Shares | |||||
| Basic Shares Outstanding | 647973 | 647973 | 18142 | 2182 | 1777 |
| Diluted Shares Outstanding | 647973 | 647973 | 18142 | 2182 | 1777 |
| Profitability Metrics | |||||
| EBITDA | (7.5M) | (4.2M) | (14.6M) | (9.6M) | (8.8M) |
| D&A | 1.3M | 774.0K | 16.0K | 15.0K | 15.0K |
| EBIT | (8.8M) | (5.0M) | (14.6M) | (9.6M) | (8.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025